New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2012
07:32 EDTVPHM, HALOViroPharma, Halozyme announce initiation of Phase 2b dose to evaluate Cinryze
ViroPharma (VPHM) and Halozyme (HALO) announced that ViroPharma has initiated its Phase 2b double blind, multicenter, dose ranging study to evaluate the safety and efficacy of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology in adolescents and adults with hereditary angioedema for prevention of HAE attacks. This double blind, cross-over, dose ranging study will be conducted in approximately 40 adolescent and adult subjects in the U.S. and Europe. The primary efficacy endpoint is the normalized number of angioedema attacks recorded during each treatment period. In addition, several secondary endpoints will be assessed, including attack severity, quality of life parameters using a novel angioedema tool, and number of angioedema attacks requiring acute treatment.
News For VPHM;HALO From The Last 14 Days
Check below for free stories on VPHM;HALO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
09:05 EDTHALOHalozyme's pancreatic cancer candidate clinical trial approved by FDA to resume
Halozyme announced that the FDA has removed the clinical hold on patient enrollment and dosing of PEGPH20 in SWOG's ongoing Phase 1b/2 clinical trial. The trial is designed to evaluate Halozyme's investigational drug PEGPH20 in combination with modified FOLFIRINOX chemotherapy in patients with metastatic pancreatic adenocarcinoma. The study will resume under a revised protocol.
September 15, 2014
09:16 EDTHALOOn The Fly: Pre-market Movers
Subscribe for More Information
September 12, 2014
20:32 EDTHALOFDA approves Baxter's HYQVIA for treatment of primary immunodeficiency
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use